LONDON (Alliance News) - ValiRx PLC on Tuesday said its Phase l/ll clinical trial of VAL201 has shown a high degree of safety.
The life science company, which focuses on cancer diagnostics and therapeutics for personalised medicine, said the compound is "well tolerated up to a putative therapeutic dose".
No drug related significant adverse events were reported.
"In light of the excellent results shown by the compound with respect to tolerability and safety in the current clinical trial, along with promising pre-clinical evidence of the compounds efficacy with respect to the treatment of endometriosis, the company has started the design of the protocol to test VAL201 for its in-human potential in the treatment of the debilitating female condition of Endometriosis," ValiRX said.
Endometriosis is a gynaecological medical condition in which cells from the lining of the uterus (endometrium) appear and flourish outside the uterine cavity, most commonly on the ovaries.
Shares in ValiRx were up 8.6% at 16.29 pence on Tuesday morning.
By Samuel Agini; samagini@alliancenews.com; @samuelagini
Copyright 2016 Alliance News Limited. All Rights Reserved.
ValiRx (VAL)